TransCode says Phase 1a trial shows 71.4% stable disease rate for TTX-MC138 in advanced solid tumors
RNAZ•TransCode reported a 71.4% stable disease rate in its ongoing Phase 1a trial of TTX-MC138 in advanced solid tumors. Some patients remained progression-free for a year.
1. Trial follow-up
TransCode released updated follow-up results from its ongoing Phase 1a trial of TTX-MC138 in advanced solid tumors. The results showed a 71.4% stable disease rate, with some patients remaining progression-free for a year.
2. Safety and next steps
The company said the treatment’s safety profile remained acceptable across tested doses, with no new tolerability signals. Exploratory biomarker work pointed to treatment-linked immune activation, and management is evaluating dose-expansion plans for selected cancers and molecularly defined patient groups.
